for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started



Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.

Official Title

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma: Companion to CALGB Treatment Studies For Previously Untreated Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM) Patients


Acute LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeMultiple MyelomaSyndromeLeukemiaNeoplasms, Plasma CellMyelodysplastic SyndromesPreleukemiaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, LymphoidAcute Diseasecytogenetic analysis


For people ages 18 years and up

  1. Patients from adjuncts are eligible if the Main Member Cytogenetics laboratory has agreed to process samples from that adjunct.
  2. Within one month of registration on CALGB 8461, register onto a CALGB treatment study for previously untreated AML, ALL, MDS, or MM patients.
  3. Simultaneously with registration on CALGB 8461, register patients within the continental United States onto CALGB 9665 (LTB).


  • Rebecca and John Moores UCSD Cancer Center
    La JollaCalifornia92093-0658United States
  • Kaiser Permanente Medical Office -Vandever Medical Office
    San DiegoCalifornia92108United States


in progress, not accepting new patients
Start Date
Alliance for Clinical Trials in Oncology
Study Type
Last Updated